Modality
Radioligand
MOA
BTKi
Target
B7-H3
Pathway
T-cell
PTSDNarcolepsy
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
~May 2020
→ ~Aug 2021
Phase 2
~Nov 2021
→ ~Feb 2023
Phase 3
~May 2023
→ ~Aug 2024
NDA/BLA
Nov 2024
→ Sep 2027
NDA/BLACurrent
NCT06515748
2,052 pts·PTSD
2024-11→2027-09·Completed
2,052 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-09-011.4y awayPh3 Readout· PTSD
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2027-09-01 · 1.4y away
PTSD
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06515748 | NDA/BLA | PTSD | Completed | 2052 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 |